RxDoctor Payments Data

Daphne Wacasey

Psychiatric/Mental Health · Smyrna, GANPI 1720227382

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.0% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,573 and has fallen 56.1% since, to $690 in 2025. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,947in general payments, 2019–2025

Across 274 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$578
  • Corium, LLC$515
  • AbbVie$475
  • Otsuka America Pharmaceutical, Inc.$429
  • Takeda Pharmaceuticals U.S.A., Inc.$359
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,47192%
  • Education$4768%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,947 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl12$4,302
Quetiapine Fumarate50$1,162
Olanzapine64$1,135
Oxcarbazepine18$924
Benztropine Mesylate29$733
Fluvoxamine Maleate12$500
Haloperidol23$472
Fluoxetine Hcl20$394
Clonazepam41$359
Lithium Carbonate24$155
Risperidone32$134
Citalopram HbrCitalopram Hydrobromide22$113
Clonidine Hcl28$86
Lamotrigine12$79
Hydroxyzine Hcl11$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$21$3413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →